Although PKM-ASO monotherapy had a limited effect in an immunodeficient mouse model of PDAC, synergy between PKM-ASO and anti-CTLA-4 immune checkpoint blockade (ICB), which targets T<sub>regs</sub>, restricted tumor growth in an immunocompetent mouse model. This evidence concerns the gene CTLA4 and neoplasm.